Di(uridine 5′-)tetraphosphate and salts thereof
View Patent ↗The present invention are directed to P 1 , P 4 -di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P 1 , P 4 -di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than the mono-, di-, or tri-acid salts, therefore, they provide an improved stability and a longer shelf life for storage. The present invention also provides methods for the synthesis of P 1 , P 4 -di(uridine 5′-)tetraphosphate, and its pharmaceutically acceptably acceptable salts thereof, and demonstrates the applicability to the production of large quantities. The methods substantially reduce the time required to synthesize diuridine tetraphosphate, for example, to three days or less.
1. A pharmaceutical formulation comprising P 1 , P 4 -di(uridine 5′-) tetraphosphate, tetrasodium salt; in a pharmaceutically acceptable carrier.
2. The pharmaceutical formulation according to claim 1 , which is in the form of an aqueous, a gel, a patch, a cream, an ointment, a suppositiory, or a solid formulation.
3. The pharmaceutical formulation according to claim 2 , wherein the pharmaceutical formulation is in the form of an aqueous solution and comprises physiologically safe excipients formulated to osmolarity between 250–350 mOsm and pH 5–9.
4. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is sterile.
5. A pharmaceutical formulation comprising P 1 , P 4 -di(uridine 5′-) tetraphosphate, tetralithium salt; or P 1 , P 4 -di(uridine 5′-)tetraphosphate, tetrapotassium salt; in a pharmaceutically acceptable carrier.
6. The pharmaceutical formulation according to claim 5 , which is in the form of an aqueous, a gel, a gel-like, a patch, a cream, an ointment, a suppositiory, or a solid formulation.
7. The pharmaceutical formulation according to claim 5 , wherein the pharmaceutical formulation is in the form of an aqueous solution and comprises physiologically safe excipients formulated to osmolarity between 250–350 mOsm and pH 5–9.
8. The pharmaceutical formulation according to claim 5 , wherein the pharmaceutical formulation is sterile.